Hereditary angioedema (HAE) attacks can be debilitating and potentially life-threatening, particularly when they affect the abdomen or airways. Recently targeted prophylactic medications have been developed and licensed and treatment practices have evolved. Long-term prophylaxis (LTP) is recommended in international guidelines to reduce attack frequency and improve quality of life (QoL) for patients.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles

